Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesUnrelated umbilical cord blood transplantation in children with immune deficiency: results of a multicenter study
Bone Marrow Transplantation, 06/23/09
Frangoul H et al. - The authors report the results of a multicenter prospective trial of unrelated CBT for PID. A total of 24 children with PID, with a median age of 1 year (range: 0.23–7.81 years) and a median weight of 10.5 kg (range: 4–24.4 kg) received unrelated CBT between 1999 and 2003.
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
Bone Marrow Transplantation, 10/15/09
Management of relapse after allo-SCT for AML and the role of second transplantation
Bone Marrow Transplantation, 10/29/09
New advances in the treatment of acute promyelocytic leukemia
International Journal of Hematology, 10/07/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the childrens oncology group
Journal of Clinical Oncology, 10/12/09
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in Childhood Leukemia Consortium Study
Journal of Clinical Oncology, 10/22/09
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
New England Journal of Medicine, 10/22/09
Sponsor
Article Search
Sponsor
Sponsor